Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
Yaël C. Cohen(Sheba Medical Center), María‐Victoria Mateos(Hospital Clínico San Carlos), Ashwani Kumar(Sher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir), Brandi Hilder(Sheba Medical Center), Hila Magen(Sheba Medical Center), Jill Vanak(Sheba Medical Center), Michelle R. Peterson(Sheba Medical Center), Albert Oriol(Institut Català d'Oncologia), Arnob Banerjee(Johnson & Johnson (United States)), Michael P. Chu(Sheba Medical Center), Michaël Sébag(Sheba Medical Center), Natalia A. Quijano Cardé(Sheba Medical Center), Irit Avivi(Tel Aviv Sourasky Medical Center), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Maria Krevvata(Janssen (United States)), Kihyun Kım(State University of New York), Emma C. Scott(Oregon Health & Science University), Daniel Morillo(Sheba Medical Center), Chang‐Ki Min(Sheba Medical Center), Sung-Soo Yoon(Sheba Medical Center), Moshe E. Gatt(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Lilla Di Scala(Sheba Medical Center), Enrique M. Ocio(Universidad de Salamanca)
Cited by 96
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k